Animal experiments indicate that angiotensin I1 can, under some circumstances stimulate the sympathetic nervous system at a number of different sites. In order to determine whether such a relationship of the renin-angiotensin and sympathetic nervous system exists in man, we increased (by intravenous infusion), or decreased (by administering the oral converting enzyme inhibitor captopril) circulating angiotensin I1 levels and monitored plasma adrenaline and noradrenaline responses. Angiotensin I1 infusions did not increase plasma catechol-amines, and lowering of angiotensin I1 by captopril treatment in patients with severe hypertension or congestive heart failure failed to alter plasma adrenaline or nor-adrenaline levels. Whether physiological levels of angiotensin I1 are capable of interacting directly with the sympathetic nervous system in man remains to be demonstrated.
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Angiotensin ZI infusion in normal subjects
Five healthy male volunteers, aged 22-28 years, were studied in the Clinical Research Centre at the University of Michigan Medical Center. Each subject received a constant intake of dietary sodium (40 mmol/day) and potassium (100 mmol/day) for 4 days prior to angiotensin I1 infusions on day five. Smoking, caffeine-containing beverages, and vigorous physical exercise were avoided. On day 5 the volunteers remained supine in bed, and a venous cannula was inserted into either arm at 0800 h, one for infusion, the other for sampling. After 60 min of 5% dextrose administration at 0.2 ml/min, angiotensin I1 (Hypertensin, Ciba) was infused incrementally at 0 3 1 *O, 2.0 and 4.0 ng.kg-].min-', each rate for 1 h. Two venous samples were drawn during dextrose administration and single samples were obtained at the completion of each infusion rate of angiotensin I1 for measurement of nor-adrenaline, adrenaline and angiotensin 11. Blood was taken into pre-chilled containers, immediately centrifuged at 4"C, and the plasma stored at -20°C until analysed. Blood pressure was measured at 10 min intervals using a standard mercury sphygmomanometer taking phase V as the diastolic endpoint: the mean of six recordings was taken as the blood pressure for each hour of infusion.
Blockade of angiotensin II formation in severe hypertension
Ten patients, nine male, one female, aged 28-53 years, five white, five black, with elevated blood pressure not controlled on conventional therapy were studied in the Clinical Research Center of the University of Michigan. Smoking and caffeine-containing drinks were avoided. In all patients, prior treatment consisting of propanolol(80 mg four times daily), hydrochlorothiazide (25 mg four times daily), and hydrallazine (50 mg four times daily) was discontinued on admission, and dose titration with the oral convertingenzyme inhibitor captopril (Squibb) started the following morning. With the patient supine in bed, captopril was administered at 2-hourly intervals in increasing dosage (25, 50, 100 and 150 mg) until a 'hypotensive' response (fall in diastolic pressure phase V of at least 10 mmHg using a conventional mercury sphygmomanometer) was achieved. A venous cannula was inserted 30 min prior to a baseline (pre-captopril) sampling, and a second venous specimen was obtained once the 'hypotensive' response was reached. Both samples were handled as described above and analysed for plasma angiotensin 11, plasma renin activity (PRA), and plasma adrenaline and nor-adrenaline.
Blockade of angiotensin II formation in congestive heart failure
The oral converting enzyme inhibitor captopril, was administered to four male patients aged 62-72 years in the Intensive Care Unit, Princess Margaret Hospital, Christchurch, New Zealand. Details of haemodynamic and hormone responses have been reported (Maslowski et al., 198 1). Each patient was in severe congestive cardiac failure (grade I11 or IV New York Heart Association classification) and had proven resistant to conventional therapy. A diet of constant sodium (3343 mmol/day) and potassium (73-100 mmol/day) was taken, and bedrest was enforced throughout the 7-10 day study. Digoxin (0.0625-0.5 mg/day) and frusemide (1 20-500 mg/day) therapy was constant in each patient for the duration of the study. After a 2-day 'run-in' period of digoxin and frusemide therapy, captopril was administered at 0730 h, 1430 h and 2330 h starting at 6.25 mg and increasing until a maximum of 150 mg per dose or an intra-arterial systolic pressure of 75 mmHg was reached. Blood samples for measurement of PRA, angiotensin 11, adrenaline and noradrenaline were drawn from an arterial catheter at 0830 h and 1530 h each day, precisely 1 h after captopril administration, and handled as described above.
Plasma angiotensin I1 (Nicholls & Espiner, 1976) and PRA (Dunn & Espiner, 1976) were measured by radioimmunoassay. The radioenzymatic technique used to measure catecholamines (Peuler & Johnson, 1977) was capable of detecting 2.5 pg/tube of adrenaline or nor-adrenaline added to plasma. There was a straight line relationship between catecholamines added to plasma and final counts per minute from the assay over a range of 1&1000 pg adrenaline or nor-adrenaline per tube. From fifteen consecutive assays the interassay coefficient of variation was 17% (adrenaline) and 1 1% (nor-adrenaline): the intra-assay coefficient of variation was 8% (adrenaline) and 7% (nor-adrenaline). All samples from any one subject were analysed in a single assay.
RESULTS

Angiotensin II infusion in normal subjects
Blood pressure did not change significantly until the highest infusion rate (4 ng.kg-'.min-') was reached ( Fig. 1) when the average increase in systolicpressure was 6 mmHg and in diastolic pressure was 9 mmHg above baseline. The pulse rate of 58.2 & 3 beats/min (mean k SEM) prior to angiotensin I1 administration was unaltered by infusion of the octapeptide (58.3 f 3.4 beats/min during the highest infusion rate). Despite increments in plasma angiotensin I1 to approximately 100 pg/ml there was no clear response of adrenaline or nor-adrenaline (Fig. 1) . Table 1 for conversion to SI units. Plasma renin activity -; plasma angiotensin 11 -.
Blockade of angiotensin II formation in seuere hypertension Captopril treatment reduced angiotensin I1 levels in eight of ten patients, and PRA increased significantly (Table 1) . On the contrary, plasma catecholamines were not altered for the group as a whole (Table I) , nor in the eight patients in whom a clear-cut decline in angiotensin I1 occurred (three showing either no change or a rise in adrenaline and nor-adrenaline levels). 
Blockade of angiotensin IIformation in congestive heart failure
Adrenaline and nor-adrenaline levels prior to administration of the oral convertingenzyme inhibitor were generally higher than values seen in healthy subjects. Captopril therapy induced clearcut decreases in plasma angiotensin I1 and increments in PRA, yet there was no fall in plasma catecholamines (Fig. 2 ) . Pulse rates declined (Fig. 2) but the change failed to reach conventional levels of statistical significance. Arterial pressure was decreased by captopril therapy (Fig. 2) .
DISCUSSION
There is no doubt that angiotensin I1 can alter the activity of the sympathetic nervous system under certain experimental circumstances (Campbell & Jackson, 1979; Peach, 1971; Yu & Dickinson, 1971) . Most of the data, however, are derived from animal studies where the doses of angiotensin I1 have been large. Whether one can extrapolate from these highly experimental animal data to physiological circumstances in man, is not known.
Few workers have looked in detail at possible actions of angiotensin I1 on the sympathetic system in man, and what data are available appear contradictory. For example, McGrath et al. (1977) and Takishita et al. (1978) reported that the sympathetic nervous system was activated by the weak angiotensin agonist saralasin, whereas neither saralasin (Carey et al., 1978; Vlachakis et al., 1978) nor angiotensin I1 infusion (Mendelsohn et al., 1980) altered plasma nor-adrenaline levels according to other authors. Likewise, blockade of angiotensin I1 formation with a converting enzyme inhibitor has been reported variously to increase (Heavey & Reid, 1978; Hulthen & Hokfelt, 1978) decrease (Curtiss et af., 1978; Turini et al., 1979) , or have no effect (Bravo & Tarazi, 1979) on plasma nor-adrenaline levels in man under various circumstances.
In order to define any action of angiotensin I1 on the sympathetic nervous system, we increased angiotensin I1 by infusion, or decreased endogenous angiotensin I1 levels with a converting enzyme inhibitor, and measured circulating catecholamine responses. Our subjects were studied under carefully controlled circumstances with attention to details of body posture, the avoidance of venepuncture just prior to sampling, and prohibition of sympathetic stimulation from caffeine or smoking. The assays used were capable of detecting minor changes in catecholamine and angiotensin I1 concentrations.
Under these conditions, we failed to observe any increase in plasma catecholamines in healthy volunteers during increments in plasma angiotensin I1 which were within physiological limits. Our results thus agree with the brief report by Mendelsohn et al. (1980) which indicated a lack of change in plasma nor-adrenaline levels across angiotensin I1 infusion in normal man. Whether greater increments in angiotensin I1 beyond those seen under normal circumstances can alter sympathetic activity in man, remains to be seen.
Conceivably, any action of angiotensin I1 on the sympathetic nervous system may be maximal at relatively low levels of circulating angiotensin 11. If this were so, increments in angiotensin I1 might not further activate the sympathetic system, but a reduction of angiotensin I1 levels from normal or high values should result in a lowering of circulating catecholamines. The current studies indicate that blockade of angiotensin I1 formation did not regularly alter circulating nor-adrenaline or adrenaline. Baseline levels of angiotensin I1 were not high in our severe hypertensives, presumably because of prior betablocker therapy, and the reduction in plasma angiotensin I1 induced by captopril was therefore not great. In contrast, both angiotensin I1 and catecholamines were elevated in the patients with cardiac failure yet no change in circulating catecholamines was noted when angiotensin I1 levels exhibited a clearcut fall.
In summary, we have shown that neither increments nor decrements in circulating angiotensin I1 alter plasma catecholamine levels, the humoral markers of sympathetic activity, in man. It is tempting to conclude therefore that angiotensin I1 has little or no action on the sympathetic nervous system, at least under the conditions of the present studies. It is possible nevertheless, that any action of angiotensin I1 was in part obscured by alterations of arterial baroreceptor input to the sympathetic system by a concomitant rise (during angiotensin I1 infusion) or fall (with captopril therapy) in blood pressure.
However no change in catecholamines occurred in our normal subjects during 0.5-2 ng.kg-'.min-' angiotensin I1 infusion rates when little or no rise in arterial pressure had occurred. Likewise, captopril monotherapy reduced blood pressure in our hypertensives by little more than 10 mmHg, thus major baroreceptor stimulation would not be expected. It seems unlikely therefore that changes in blood pressure obscured an action of angiotensin I1 on the sympathetic nervous system.
A complicating issue in the interpretation ofcaptopril studies is the fact that bradykinin levels would be expected to rise along with falls in angiotensin 11. Since bradykinin, like angiotensin I1 has been reported to stimulate adrenal medullary secretion (Feldberg & Lewis, 1964) it is conceivable that a reduction in sympathetic stimulation from falling angiotensin I1 was counterbalanced by augmented stimulation by rising bradykinin levels. Whether there are in fact distinct increases in plasma bradykinin across captopril treatment is open to dispute, and refinements of current methodologies for the measurement of this labile peptide are required for clarification.
A final note of caution must be made regarding interpretation of the present results. There is some uncertainty whether plasma catecholamines reflect accurately the state of activity of the sympathetic nervous system under all circumstances. For example, Mancia et al. (1979) using a neck chamber technique showed that in normal subjects a reduction of baroreceptor activity had pressor effects without a concomitant change in plasma noradrenaline. Since the overspill of transmitter from sympathetic nerve endings into the circulation is small, and because the clearance rate of nor-adrenaline released into plasma will almost certainly be altered under certain conditions, plasma levels of nor-adrenaline must be interpreted with caution.
The current studies in man fail to demonstrate any action of angiotensin I1 to alter plasma adrenaline or nor-adrenaline levels, the humoral markers of sympathetic activity.
Whether angiotensin I1 at physiological concentrations is capable of interacting directly with the sympathetic nervous system in man remains to be demonstrated.
